0000950103-17-002563.txt : 20170317 0000950103-17-002563.hdr.sgml : 20170317 20170317162250 ACCESSION NUMBER: 0000950103-17-002563 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170313 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20170317 DATE AS OF CHANGE: 20170317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 17698341 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 dp74141_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 17, 2017 (March 13, 2017)

 

 

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   001-14956   98-0448205
(State or other jurisdiction
of incorporation)		   (Commission
file number)		   (IRS Employer
Identification No.)
         
2150 St. Elzéar Blvd. West, Laval, Quebec, Canada H7L 4A8
(Address of principal executive offices) (Zip Code)
 

(514) 744-6792 

(Registrant's telephone number, including area code)

 

N/A 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

William A. Ackman and Stephen Fraidin, both members of the Board of Directors (the “Board”) of Valeant Pharmaceuticals International, Inc. (the “Company”) and affiliates of Pershing Square Capital Management, L.P. (“Pershing Square”), advised the Company on March 13, 2017 that they have decided not to stand for reelection to the Board at the next annual meeting. Messrs. Ackman and Fraidin made this decision in light of the sale by Pershing Square and affiliated entities of all Company shares held by them and in order to dedicate more time to other Pershing Square portfolio companies and investment opportunities. Messrs. Ackman and Fraidin will continue to serve as directors on the Board until their terms end at the Company’s 2017 annual meeting of shareholders. Mr. Ackman currently serves as the chairman of the Finance and Transactions Committee of the Board, and Mr. Fraidin currently serves as a member of the Conduct and Compliance Committee and the Talent and Compensation Committee of the Board. The determinations of Messrs. Ackman and Fraidin not to stand for reelection was not a result of any disagreement with the Company or the Board.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 17, 2017

 

  VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
   
   
 By: /s/ Christina Ackermann
  Christina Ackermann
  Executive Vice President and General Counsel